Login to Your Account

Other News To Note

Wednesday, October 17, 2012
• BioLineRx Ltd., of Jerusalem, said a recent analysis of data from its Phase IIb EAGLE trial testing orally available GABA-enhanced antipsychotic BL-1020 in schizophrenia indicated that the drug demonstrated a significant increase in efficacy at improving cognitive impairment associated with the condition, as compared to the original analysis of the study.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription